Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

VR-pupillometri ved kognitiv svikt

8. november 2026 oppdatert av: Victor Spoormaker, Max-Planck-Institute of Psychiatry

Oppgave-evokert pupillometri ved AD, MCI og depresjonsrelatert kognitiv svikt

With disease-modifying therapies emerging for dementia and related conditions, identifying cognitive decline as early as possible is increasingly important. This prospective, single-center, repeated-measures study evaluates whether VR-based eye-tracking pupillometry can provide a practical, non-invasive biomarker of cognitive impairment and its progression over time. Pupil responses are linked to brain arousal systems relevant to cognitive dysfunction, including the locus coeruleus, which is affected early in Alzheimer's disease. Adults aged 18-80 years will be assigned to one of four cohorts (n=35 per cohort): i) Alzheimer's disease (supported by CSF biomarkers), ii) mild cognitive impairment (MCI) without Alzheimer's Disease, iii) depressive disorder with cognitive impairment, iv) healthy controls. Participants will undergo initial assessments at baseline and follow-up visits after 6, 12 and 18 months. At each visit, pupil responses and behavioral metrics are recorded during a pupillary light reflex paradigm, a resting-state fixation block, a working-memory task (N-back), and a reward task. Pupillometric and behavioral metrics will be compared across cohorts and related to routine neuropsychological measures (MoCA, CERAD) and available clinical biomarkers (CSF markers; blood biomarkers). The primary objective is to determine whether task-evoked pupil response profiles sensitively quantify cognitive impairment, differ between cohorts, and track change over time. The long-term goal is to validate an easy-to-use, outpatient-compatible assessment to support objective characterization and monitoring of cognitive disorders.

Studieoversikt

Detaljert beskrivelse

Cognitive performance typically declines with age and is usually accompanied by attention and memory deficits. While such changes can be consistent with normal ageing, they may also reflect affective disorders or early stages of neurodegenerative diseases (e.g. Alzheimer's Disease; AD). In clinical practice, neurocognitive tests are commonly used to distinguish age-appropriate change from pathological decline. As these tests quantify behavioral performance, they are better at detecting cognitive decline, once measurable deficits are manifested. However, they have limited sensitivity to subtle changes that can precede overt clinical symptoms by several years. This study evaluates a diagnostic approach based on pupil dilation measurements that may support earlier detection and longitudinal monitoring, potentially enabling earlier interventions.

Pupillometry provides a noninvasive index of pupil dynamics linked to arousal systems relevant to cognition, including the locus coeruleus-noradrenergic (LC-NA) system. LC-NA activity is coupled to pupil dilation via autonomic pathways, and this coupling has been demonstrated across animal and human studies. Given its widespread projections, the LC-NA system is implicated in psychiatric and neurological conditions through roles in arousal regulation, stress responsivity, attention, and memory. Pupillometry in Alzheimer's disease has often been examined using pupillary light reflex paradigms. However, simple light-flash measures may be less informative in early-stage impairment because pupil responses vary with cognitive state and task demands and do not provide a uniform, task-independent readout of LC-linked function. Accordingly, analyzing pupil responses during and immediately following cognitive tasks may be better suited to capturing subtle dysfunction relevant to prodromal processes, with light-reflex alterations potentially becoming more apparent once impairment is established. In prior work, the investigators observed pupil diameter increased with working-memory load during an N-back task. Most participants showed the expected increase in pupil dilation with task difficulty, whereas a subset exhibited pronounced atypical pupil responses despite only slight differences on standard neurocognitive measures. Building on these principles, this study uses a VR-based assessment to examine adults presenting with early, non-specific cognitive complaints. By systematically recording pupil dynamics during and following cognitive paradigms, the investigators aim to obtain readouts of LC-NA system function that may support differential diagnosis among conditions with overlapping clinical presentations (e.g. depression-related cognitive impairment vs. early dementia).

At each visit, participants are fitted with a VR headset by trained study personnel and complete VR-based assessments with concurrent eye tracking and behavioral performance recording. Assessments are conducted at baseline (T0) and repeated after 6 months (T1), 12 (T2) and 18 months (T3). At each visit, pupil responses and task performance are recorded during a pupillary light reflex paradigm, a resting-state fixation block, a working-memory task (N-back), and a reward task. Participants also complete routine neuropsychological testing, including the Montreal Cognitive Assessment (MoCA) and the CERAD battery comprising semantic fluency, Boston Naming Test, Mini-Mental State Examination (MMSE), word list learning, word list delayed recall, word list recognition, figure copying, figure delayed recall, phonemic fluency, and Trail Making Test. Additional assessments include the Bayer Activities of Daily Living scale (Bayer-ADL) and the Geriatric Depression Scale (GDS), as well as questionnaires assessing subjective cognitive impairment (FLei) and childhood adversity (CTQ). Sociodemographic data are recorded, including age, sex, education (years of schooling), and occupation. Blood is collected for routine laboratory measures and blood-based biomarker analyses (including phosphorylated tau 217), and clinical data from routine care are linked where available. In some cases, cerebrospinal fluid biomarkers from routine clinical evaluation are available and linked, including AD pathology markers (amyloid-β and tau measures).

Pupillometric and behavioral measures will be compared across cohorts and evaluated longitudinally across follow-up visits. Measures will also be related to routine neuropsychological assessment, as well as available clinical biomarkers (CSF amyloid-β and tau measures blood-based biomarkers and anatomical neuroimaging sequences). Prior observations suggest that pupil dilation scales with cognitive load and that task-evoked pupil responses can differ, even when standard neurocognitive measures show only subtle differences. The investigators hypothesize that task-evoked pupil response patterns will differ between cohorts and may be sensitive to change over time.

Studietype

Observasjonsmessig

Registrering (Antatt)

140

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Bavaria
      • München, Bavaria, Tyskland, 80804
        • Rekruttering
        • Max Planck Institute of Psychiatry
        • Ta kontakt med:
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Adults aged 18-80 years will be recruited at the Max Planck Institute of Psychiatry (Munich, Germany) from inpatient wards and outpatient clinics. Patients have a suspected or confirmed clinical diagnosis of Alzheimer's disease, mild cognitive impairment, or depressive disorder with cognitive impairment. Routine clinical measures (neuropsychological testing and, CSF biomarkers, blood biomarkers, imaging) will be linked to study pupillometry outcomes.

Beskrivelse

Inclusion Criteria:

  1. Written informed consent.
  2. Age 18-80 years.
  3. Ability to read and understand German.
  4. For patient cohorts: suspected or confirmed diagnosis of AD/MCI/depressive disorder with cognitive impairment according to clinical assessment and routine documentation.

Exclusion Criteria:

  1. Acute suicidality (e.g. BDI suicidality item > 1).
  2. Change of psychotropic medication within the last 4 weeks.
  3. Lifetime psychotic disorder (ICD-10 F20-29).
  4. Lack of capacity to consent.
  5. Lifetime bipolar disorder (ICD-10 F31).
  6. Acute substance abuse or harmful use of alcohol or other psychoactive substances.
  7. Parkinson's syndrome (ICD-10 G20).
  8. Multiple sclerosis (ICD-10 G35).
  9. Stroke within the last 12 months.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Alzheimer's Disease

Participants with complaints of cognitive deficits and a diagnosis of Alzheimer's disease (AD) supported by cerebrospinal fluid (CSF) biomarker profile, where available.

Mild Cognitive Impairment without Alzheimer's Disease

Participants with complaints of cognitive deficits meeting criteria for mild cognitive impairment without evidence of Alzheimer's disease (CSF biomarkers not consistent with AD).

Depressive Disorder With Cognitive Impairment

Participants with complaints of cognitive impairment and no evidence of Alzheimer's pathology; deficits most consistent with depressive disorder.

Healthy Controls

Age-matched healthy volunteers.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Task-evoked pupil dilation during N-Back
Tidsramme: Baseline

Pupil response metrics (mean relative pupil diameter in each condition) recorded with VR eye tracking during the N-back task for each condition (fixation, 0-back, 1-back, 2-back).

Baseline

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Resting-state pupil dynamics
Tidsramme: Baseline, 6, 12 and 18 months.

Mean and variability of pupil diameter during resting fixation.

Baseline, 6, 12 and 18 months.
Reward-task pupil response
Tidsramme: Baseline, 6, 12 and 18 months.

Pupil response metrics (mean relative pupil diameter in each condition) recorded with VR eye tracking during each condition (reward, control).

Baseline, 6, 12 and 18 months.
N-back behavioral performance
Tidsramme: Baseline, 6, 12 and 18 months.

Behavioral performance during the VR N-back task, quantified as accuracy and reaction time for each load condition ( 0-, 1-, 2-back).

Baseline, 6, 12 and 18 months.
Montreal Cognitive Assessment (MoCA)
Tidsramme: Baseline, 6, 12 and 18 months.

Global cognitive screening tool used to quantify overall cognitive impairment. Range: 0-30; higher scores indicate better cognitive performance.

Baseline, 6, 12 and 18 months.
CERAD cognitive battery (CERAD-Plus), norm-referenced z-scores
Tidsramme: Baseline, 6, 12 and 18 months.

CERAD-Plus subtests include semantic fluency, Boston Naming Test, word list learning, word list delayed recall, word list recognition, figure copying, figure delayed recall, phonemic fluency, and Trail Making Test. The subtests will be evaluated using age-/education-adjusted norm-referenced z-scores. A z-score of 0 corresponds to the normative mean; higher z-scores indicate better cognitive performance and lower z-scores indicate worse performance.

Baseline, 6, 12 and 18 months.
Bayer Activities of Daily Living (Bayer-ADL)
Tidsramme: Baseline, 6, 12 and 18 months.

Functional status measured using the Bayer-ADL mean item score (quotient). Range: 1.00-10.00. Higher scores indicate worse functional impairment (more difficulty with activities of daily living).

Baseline, 6, 12 and 18 months.
Geriatric Depression Scale
Tidsramme: Baseline, 6, 12 and 18 months.

Geriatric Depression Scale, 30-item version (GDS-30), total score (depressive symptoms). Range: 0-30; higher scores indicate more depressive symptoms.

Baseline, 6, 12 and 18 months.
Subjective cognitive impairment (Fragebogen zur geistigen Leistungsfähigkeit; FLei), total score
Tidsramme: Baseline, 6, 12 and 18 months.

35-item self-report assessing cognitive difficulties over the last 6 months (0-4 per item). Range: 0-140. Higher scores indicate greater subjective cognitive impairment (more perceived difficulties).

Baseline, 6, 12 and 18 months.
Childhood Trauma Questionnaire (CTQ)
Tidsramme: Baseline.

Retrospective recall-based measures administered to adults. Used to determine experiences of childhood trauma. Higher scores indicate greater childhood adversity.

Baseline.
Blood-based biomarkers
Tidsramme: Baseline, 6, 12 and 18 months.

Blood biomarker concentrations assessed from collected blood samples, including phosphorylated tau 217 (p-tau217) and Aβ1-42/Aβ1-40 ratio.

Baseline, 6, 12 and 18 months.
CSF Alzheimer's disease pathology markers
Tidsramme: Baseline.

CSF biomarkers from routine clinical evaluation where available, including Aβ1-42, Aβ1-40, Aβ1-42/Aβ1-40 ratio, total tau, and phosphorylated tau.

Baseline.
Task-evoked pupil dilation during N-Back
Tidsramme: Baseline, 6, 12 and 18 months.

Pupil response metrics (mean relative pupil diameter in each condition; load-dependent slope across conditions) recorded with VR eye tracking during the N-back task for each condition (fixation, 0-back, 1-back, 2-back).

Baseline, 6, 12 and 18 months.

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Between-group differences in N-back pupil metrics
Tidsramme: Baseline, 6, 12 and 18 months.

Comparison of the primary N-back pupil load metric across the four cohorts (Alzheimer's disease, mild cognitive impairment, depressive disorder with cognitive impairment, healthy controls).

Baseline, 6, 12 and 18 months.
Association between task-evoked pupil responses and cognitive test performance
Tidsramme: Baseline, 6, 12 and 18 months.

Association between the N-back pupil metrics and cognitive performance measures (MoCA total score; CERAD-Plus subtest z-scores).

Baseline, 6, 12 and 18 months.
Association between task-evoked pupil responses and AD pathology markers
Tidsramme: Baseline through 18 months, using biomarker time points available

Association between the N-back pupil metrics and available biomarkers of AD pathology (CSF and blood-based biomarkers).

Baseline through 18 months, using biomarker time points available
Change from baseline in N-back pupil metrics
Tidsramme: Baseline, 6, 12 and 18 months.

Within-participant change from baseline in the prespecified N-back pupil load metric

Baseline, 6, 12 and 18 months.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Victor I. Spoormaker, PhD, Max-Planck-Institute of Psychiatry

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. mai 2025

Primær fullføring (Antatt)

31. desember 2027

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

12. januar 2026

Først innsendt som oppfylte QC-kriteriene

3. februar 2026

Først lagt ut (Faktiske)

11. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

8. november 2026

Sist bekreftet

1. februar 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere